Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy

• DOI: 10.18502/cmm.6.4.5331
• Publication Date: 2021-04-14T07:25:59Z
• Authors: Sviatlana L. Kand...; Kseniya S. Baslyk; Alexandr A. Migas; Anna V. Hill; Oleg I. Bydanov; Volha A. Mishkova; Olga V. Aleinikova
• Keywords: Hematology

Background and Purpose:Children with acute myeloid leukemia relapses of are at high risk developing fungal infections need antifungal prophylaxis. This study aimed to compare the efficacy toxicity two different dosage regimens voriconazole (VRCZ) during prophylactic administration in children malignancyand neutropenia. Materials Methods:This prospective was conducted Belarusian Research Center for Pediatric Oncology, Hematology, Immunology fromMay 2017 December 2019. The present included 21 Caucasian patients malignant hematological diseases (20 1 patient Non-Hodgkin's lymphoma) aged 2-18 years. All were randomly divided into groups that received VRCZ Patients “high-dose” group VRCZat a dose 9 mg/kg twice day PO, or 8 IV without loading (children 2-11 adolescents 12-14 years old with. Results:In high-dosegroup (n=20 episodes prophylaxis), invasive (IFI) signs recorded one (5%) case. In low-dose episodes), IFI observed six (30%) cases (P=0.0375). residual serum concentration significantly higher who doses (p <0.0001). Most (n=6, 86%) had mean value (i.e.,) Conclusion:The likelihood lower prophylactically (P=0.0375) ≥ 0.74 μg/ml medication (P=0.0258). Residual reached plateau by sixth treatment. children, only highly significant factor affecting metabolism VRCZ.